P-glycoprotein substrates and antagonists cluster into two distinct groups

Stefania Scala, Nadia Akhmed, U. S. Rao, Ken Paull, Lu Bin Lan, Bruce Dickstein, Jong Seok Lee, Galal H. Elgemeie, Wilfred D. Stein, Susan E. Bates

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

To gather further insight into the interaction between P-glycoprotein (Pgp) and its substrates, 167 compounds were analyzed in multidrug resistant human colon carcinoma cells. These compounds were selected from the National Cancer institute Drug Screen repository using computer-generated correlations with known Pgp substrates and antagonists. The compounds were prospectively defined as Pgp substrates if cytotoxicity was increased ≤4-fold by the addition of cyclosporin A (CsA) and as Pgp antagonists if inhibition of efflux increased rhodamine accumulation by 4-fold. Among the 84 agents that met either criterion, 35 met only the criterion for substrates, 42 met only the criterion for antagonists, and only seven met both criteria. Thus, compounds interacting with PgP form two distinct groups: one comprising cytotoxic compounds that are transported and have poor or no antagonistic activity and a second comprising compounds with antagonistic activity and no evidence of significant transport. Vinblastine accumulation and kinetic studies performed on a subset of 18 compounds similarly differentiated substrates and antagonists, but inhibition of 3H-azidopine labeling and induction of ATPase activity did not. These data support an emerging concept of Pgp in which multiple regions instead of specific sites are involved in drug transport.

Original languageEnglish
Pages (from-to)1024-1033
Number of pages10
JournalMolecular Pharmacology
Volume51
Issue number6
Publication statusPublished - Jun 1997

Fingerprint

P-Glycoprotein
Rhodamines
National Cancer Institute (U.S.)
Vinblastine
Pharmaceutical Preparations
Cyclosporine
Adenosine Triphosphatases
Colon
Carcinoma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L. B., Dickstein, B., ... Bates, S. E. (1997). P-glycoprotein substrates and antagonists cluster into two distinct groups. Molecular Pharmacology, 51(6), 1024-1033.

P-glycoprotein substrates and antagonists cluster into two distinct groups. / Scala, Stefania; Akhmed, Nadia; Rao, U. S.; Paull, Ken; Lan, Lu Bin; Dickstein, Bruce; Lee, Jong Seok; Elgemeie, Galal H.; Stein, Wilfred D.; Bates, Susan E.

In: Molecular Pharmacology, Vol. 51, No. 6, 06.1997, p. 1024-1033.

Research output: Contribution to journalArticle

Scala, S, Akhmed, N, Rao, US, Paull, K, Lan, LB, Dickstein, B, Lee, JS, Elgemeie, GH, Stein, WD & Bates, SE 1997, 'P-glycoprotein substrates and antagonists cluster into two distinct groups', Molecular Pharmacology, vol. 51, no. 6, pp. 1024-1033.
Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Molecular Pharmacology. 1997 Jun;51(6):1024-1033.
Scala, Stefania ; Akhmed, Nadia ; Rao, U. S. ; Paull, Ken ; Lan, Lu Bin ; Dickstein, Bruce ; Lee, Jong Seok ; Elgemeie, Galal H. ; Stein, Wilfred D. ; Bates, Susan E. / P-glycoprotein substrates and antagonists cluster into two distinct groups. In: Molecular Pharmacology. 1997 ; Vol. 51, No. 6. pp. 1024-1033.
@article{f86e777a32ca4c3a9f72cb6a59114cf3,
title = "P-glycoprotein substrates and antagonists cluster into two distinct groups",
abstract = "To gather further insight into the interaction between P-glycoprotein (Pgp) and its substrates, 167 compounds were analyzed in multidrug resistant human colon carcinoma cells. These compounds were selected from the National Cancer institute Drug Screen repository using computer-generated correlations with known Pgp substrates and antagonists. The compounds were prospectively defined as Pgp substrates if cytotoxicity was increased ≤4-fold by the addition of cyclosporin A (CsA) and as Pgp antagonists if inhibition of efflux increased rhodamine accumulation by 4-fold. Among the 84 agents that met either criterion, 35 met only the criterion for substrates, 42 met only the criterion for antagonists, and only seven met both criteria. Thus, compounds interacting with PgP form two distinct groups: one comprising cytotoxic compounds that are transported and have poor or no antagonistic activity and a second comprising compounds with antagonistic activity and no evidence of significant transport. Vinblastine accumulation and kinetic studies performed on a subset of 18 compounds similarly differentiated substrates and antagonists, but inhibition of 3H-azidopine labeling and induction of ATPase activity did not. These data support an emerging concept of Pgp in which multiple regions instead of specific sites are involved in drug transport.",
author = "Stefania Scala and Nadia Akhmed and Rao, {U. S.} and Ken Paull and Lan, {Lu Bin} and Bruce Dickstein and Lee, {Jong Seok} and Elgemeie, {Galal H.} and Stein, {Wilfred D.} and Bates, {Susan E.}",
year = "1997",
month = "6",
language = "English",
volume = "51",
pages = "1024--1033",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - P-glycoprotein substrates and antagonists cluster into two distinct groups

AU - Scala, Stefania

AU - Akhmed, Nadia

AU - Rao, U. S.

AU - Paull, Ken

AU - Lan, Lu Bin

AU - Dickstein, Bruce

AU - Lee, Jong Seok

AU - Elgemeie, Galal H.

AU - Stein, Wilfred D.

AU - Bates, Susan E.

PY - 1997/6

Y1 - 1997/6

N2 - To gather further insight into the interaction between P-glycoprotein (Pgp) and its substrates, 167 compounds were analyzed in multidrug resistant human colon carcinoma cells. These compounds were selected from the National Cancer institute Drug Screen repository using computer-generated correlations with known Pgp substrates and antagonists. The compounds were prospectively defined as Pgp substrates if cytotoxicity was increased ≤4-fold by the addition of cyclosporin A (CsA) and as Pgp antagonists if inhibition of efflux increased rhodamine accumulation by 4-fold. Among the 84 agents that met either criterion, 35 met only the criterion for substrates, 42 met only the criterion for antagonists, and only seven met both criteria. Thus, compounds interacting with PgP form two distinct groups: one comprising cytotoxic compounds that are transported and have poor or no antagonistic activity and a second comprising compounds with antagonistic activity and no evidence of significant transport. Vinblastine accumulation and kinetic studies performed on a subset of 18 compounds similarly differentiated substrates and antagonists, but inhibition of 3H-azidopine labeling and induction of ATPase activity did not. These data support an emerging concept of Pgp in which multiple regions instead of specific sites are involved in drug transport.

AB - To gather further insight into the interaction between P-glycoprotein (Pgp) and its substrates, 167 compounds were analyzed in multidrug resistant human colon carcinoma cells. These compounds were selected from the National Cancer institute Drug Screen repository using computer-generated correlations with known Pgp substrates and antagonists. The compounds were prospectively defined as Pgp substrates if cytotoxicity was increased ≤4-fold by the addition of cyclosporin A (CsA) and as Pgp antagonists if inhibition of efflux increased rhodamine accumulation by 4-fold. Among the 84 agents that met either criterion, 35 met only the criterion for substrates, 42 met only the criterion for antagonists, and only seven met both criteria. Thus, compounds interacting with PgP form two distinct groups: one comprising cytotoxic compounds that are transported and have poor or no antagonistic activity and a second comprising compounds with antagonistic activity and no evidence of significant transport. Vinblastine accumulation and kinetic studies performed on a subset of 18 compounds similarly differentiated substrates and antagonists, but inhibition of 3H-azidopine labeling and induction of ATPase activity did not. These data support an emerging concept of Pgp in which multiple regions instead of specific sites are involved in drug transport.

UR - http://www.scopus.com/inward/record.url?scp=0030976879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030976879&partnerID=8YFLogxK

M3 - Article

C2 - 9187269

AN - SCOPUS:0030976879

VL - 51

SP - 1024

EP - 1033

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -